Mark Peterson

Reading the market’s next move: deconstructing the deals and disruptions that move the world.

MP
Editor
Mark Peterson

About This Column

Mark Peterson is an analyst of the maneuvers that redefine global industry. Formerly the voice behind Strategic Transactions & Market Disruptors, Mark has expanded his lens to investigate how high-stakes deals serve as the ultimate signals of future market dominance. He specializes in deconstructing the "why" behind corporate maneuvers - dissecting M&A activity, IPOs, and strategic realignments to uncover what they telegraph about the next decade of growth and competition. His column is a destination for those who want to understand the intersection of capital, technology, and the evolving corporate landscape.

Displaying items 101-120 of 883 in total

Audax’s Power Play: Poaching a Blackstone Vet to Redefine PE Growth

Read full article
Audax’s Power Play: Poaching a Blackstone Vet to Redefine PE Growth

AI at Work: Can an Open Standard Finally Tame Corporate Data Chaos?

Read full article
AI at Work: Can an Open Standard Finally Tame Corporate Data Chaos?

Jacobi Productions' High-Stakes Gambit on Authenticity in Hollywood North

Read full article
Jacobi Productions' High-Stakes Gambit on Authenticity in Hollywood North

NuScale's $1.9B Bet: Burning Cash to Build the Nuclear Future

Read full article
NuScale's $1.9B Bet: Burning Cash to Build the Nuclear Future

Context Therapeutics' Calculated Cut: A High-Stakes Bet on Bispecifics

Read full article
Context Therapeutics' Calculated Cut: A High-Stakes Bet on Bispecifics

Greycoat's US Gambit: AIM Science Fuels 8.5x Surge in Feline Health Market

Read full article
Greycoat's US Gambit: AIM Science Fuels 8.5x Surge in Feline Health Market

Beyond the Scalpel: A Med Society’s High-Stakes Bet on Business Acumen

Read full article
Beyond the Scalpel: A Med Society’s High-Stakes Bet on Business Acumen

The AI Co-Scientist: Inside the BMS-Schrödinger Deal Reshaping Pharma R&D

Read full article
The AI Co-Scientist: Inside the BMS-Schrödinger Deal Reshaping Pharma R&D

Alteogen’s $365M Deal Cements Subcutaneous Delivery as Pharma’s New Frontier

Read full article
BriefGlance

Eton's Masterstroke: A Bid for Full-Spectrum Hemangioma Market Dominance

Read full article
Eton's Masterstroke: A Bid for Full-Spectrum Hemangioma Market Dominance

The New Blueprint for Trust: Fideo & Sigma360 Signal a New Era in Risk

Read full article
The New Blueprint for Trust: Fideo & Sigma360 Signal a New Era in Risk

Decade's $85M Gambit: Inside the Record Seed Round to Forge Brazil's Next Millionaires

Read full article
Decade's $85M Gambit: Inside the Record Seed Round to Forge Brazil's Next Millionaires

The Insurance Shake-Up: Niche Awards Signal a Hyper-Personalized Future

Read full article
The Insurance Shake-Up: Niche Awards Signal a Hyper-Personalized Future

Taipei's Medtech Gambit: Building an AI Healthcare Bridge to Japan

Read full article
Taipei's Medtech Gambit: Building an AI Healthcare Bridge to Japan

VestGen's AI Play Signals a New Blueprint for Wealth Management

Read full article
BriefGlance

PalTech's Strategic Asset: Engineering a Culture That Outperforms Code

Read full article
PalTech's Strategic Asset: Engineering a Culture That Outperforms Code

Cuban's AI Gambit: A Bet on Youth to Redefine Tech's Future

Read full article
Cuban's AI Gambit: A Bet on Youth to Redefine Tech's Future

Jones Act at a Crossroads: Billions at Stake as Waiver Debate Looms

Read full article
Jones Act at a Crossroads: Billions at Stake as Waiver Debate Looms

The $725M Heist: How Digital Ghosts Are Hijacking the Supply Chain

Read full article
The $725M Heist: How Digital Ghosts Are Hijacking the Supply Chain

AI's Day of Reckoning: A Hundredfold Security Gap Divides the Industry

Read full article
AI's Day of Reckoning: A Hundredfold Security Gap Divides the Industry
UCID: 2